InvestorsHub Logo
Followers 800
Posts 50852
Boards Moderated 1
Alias Born 12/12/2004

Re: None

Tuesday, 09/20/2016 9:07:40 AM

Tuesday, September 20, 2016 9:07:40 AM

Post# of 2026
"We have a growing body of data pointing to the powerful liver protective properties of CF102. This supports our ongoing Phase II trial of CF102 as a second line treatment for hepatocellular carcinoma. These preclinical data are also valuable in showing CF102 holds promise in the treatment of NASH and other liver diseases and injuries," stated Can-Fite CEO Dr. Pnina Fishman."

DUKE BASKETBALL and NOTRE DAME FOOTBALL

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CANF News